Purpose

The purpose of this study is to test whether receiving methylprednisolone before surgery will reduce the side effects of having surgery, such as infections and longer hospital stays.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥18 years at the time of consent. - Scheduled to undergo elective major hepatectomy (defined by CPT codes 47122 [trisegmentectomy], 47125 [total left hepatectomy], or 47130 [total right hepatectomy]). - In addition to major hepatectomy, as defined above, patients may undergo additional partial hepatectomy or operative ablation.

Exclusion Criteria

  • Known or documented adverse reactions to methylprednisolone. - Unable to receive methylprednisolone because of coexisting medical conditions. - Long-term (≥10-day course) systemic corticosteroid use, regardless of dose, if doses have been administered within 30 days of the planned date of surgery. This will not apply to steroids administered, in accordance with the standard of care, with preoperative chemotherapy. The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive-airway diseases), eye drops, and local injections (e.g., intra-articular). - Significant chance (based on surgeon judgement) of being unable to successfully complete surgery because of unresectability. - Expected or highly likely to undergo concomitant major organ resection (stomach, pancreas, colon, rectum, uterus, ovaries, bladder, kidney, small bowel). - Expected or highly likely to undergo biliary tree reconstruction via creation of a biliary-enteric anastomosis. - Scheduled to undergo concurrent insertion of a hepatic artery infusion pump device. - Estimated renal dysfunction defined by any of the following: creatinine clearance ≤40 mL/min as calculated by the Cockcroft-Gault Equation, currently on hemodialysis, currently on peritoneal dialysis. - Dependence on mechanical ventilation before surgery. - Pregnant or nursing (lactating), where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. - Known at the time of enrollment to have a bacterial infection that is expected to be present at the time of surgery or receipt of systemic antibiotic or antifungal therapy within 7 days before surgery. - Unable to provide informed consent

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Cohort 1: Methylprednisolone
  • Drug: Methylprednisolone
    single preoperative dose of methylprednisolone
No Intervention
Cohort 2: No Steroid

Recruiting Locations

Memorial Sloan Kettering Commack (Data Collection Only)
Commack, New York 11725
Contact:
Michael D'Angelica, MD
212-639-3226

Memoral Sloan Kettering Westchester (Data Collection Only)
Harrison, New York 10604
Contact:
Michael D'Angelica, MD
212-639-3226

Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York 10065
Contact:
Michael D'Angelica, MD
212-639-3226

More Details

Status
Recruiting
Sponsor
Memorial Sloan Kettering Cancer Center

Study Contact

Michael D'Angelica, MD
212-639-3226
dangelim@MSKCC.ORG

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.